C2orf50 Inhibitors
Staurosporine is a broad-spectrum kinase inhibitor that can suppress the activity of a wide array of kinases; if C2orf50 has kinase activity or interacts with kinases, Staurosporine can affect its function. LY294002 and PD98059 target key components within the PI3K/Akt and MAPK/ERK pathways, respectively, which are central to regulating cell survival, proliferation, and differentiation. Rapamycin is well-known for its role in inhibiting mTOR, which can control cell growth and may intersect with C2orf50's function. Cyclopamine and SB431542 inhibit the Hedgehog and TGF-β signaling pathways, respectively, which could be relevant if C2orf50 plays a role in these pathways.
Bortezomib and MG132 are proteasome inhibitors that could stabilize proteins by preventing their degradation, potentially impacting the turnover of C2orf50 if it is rapidly degraded under normal conditions. Epigenetic modifiers such as 5-Azacytidine and Trichostatin A can alter gene expression and chromatin structure, which may affect the expression level or function of C2orf50. Y-27632, a ROCK inhibitor, can influence the cytoskeleton organization, and if C2orf50 is involved in this process, its function could be impacted.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A kinase inhibitor, can inhibit a wide range of protein kinases that C2orf50 may be associated with. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, can disrupt PI3K/Akt signaling pathways potentially involving C2orf50. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor, can inhibit the MAPK/ERK pathway, potentially affecting C2orf50 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, can affect cell growth and protein synthesis that C2orf50 may regulate. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
A Hedgehog signaling pathway inhibitor, can affect pathways that C2orf50 may be part of. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, can affect stress response and apoptosis, potentially involving C2orf50. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
A TGF-β receptor inhibitor, can affect cellular differentiation processes that C2orf50 may influence. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, can affect protein degradation pathways that may involve C2orf50. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor, can alter gene expression and could affect C2orf50 regulation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor, can change chromatin structure and gene expression, potentially impacting C2orf50. | ||||||